Cytokine gene polymorphisms of TNFα, IL-6, IL-10, TGFβ and IFNγ in the saudi population

British Journal of Biomedical Science

Volumn 70, Issue 3, 2013, Pages 104-109

  Alhamad, E H ^a   Cal, J G ^a   Shakoor, Z ^b   Almogren, A ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

Author keywords

Cytokines; Genetic; Genotype; Polymorphism

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

AFRICAN AMERICAN; ARTICLE; COMPARATIVE STUDY; DNA EXTRACTION; DNA POLYMORPHISM; ETHNICITY; EUROPEAN AMERICAN; GENOTYPE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SAUDI ARABIA;

EID: 84889254286     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2013.11669944     Document Type: Article

References (54)

1. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003; 56 (7): 481-90
2. Stoycheva MV, Murdjeva MA. Cytokines in Salmonella infections. Folia Med (Plovdiv) 2004; 46 (4): 5-10
3. Scheller J, Ohnesorge N, Rose-John S. Interleukin-6 transsignalling in chronic inflammation and cancer. Scand J Immunol 2006; 63 (5): 321-9
4. Hollegaard MV, Bidwell JL. Cytokine gene polymorphism in human disease: on-line databases, Supplement 3. Genes Immun 2006; 7 (4): 269-76
5. Rood MJ, van Krugten MV, Zanelli E et al. TNF-308A and HLA-DR3 alleles contribute independently to susceptibility to systemic lupus erythematosus. Arthritis Rheum 2000; 43 (1): 129-34
6. Chertow GM, Milford EL. Poorer graft survival in African- American transplant recipients cannot be explained by HLA mismatching. Adv Ren Replace Ther 1997; 4 (1): 40-5
7. Liu Z, Colpaert S, D'Haens GR et al. Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production. J Immunol 1999; 163 (7): 4049-57
8. Verhoef CM, Van Roon JA, Vianen ME, Glaudemans CA, Lafeber FP, Bijlsma JW. Lymphocyte stimulation by CD3-CD28 enables detection of low T cell interferon-gamma and interleukin-4 production in rheumatoid arthritis. Scand J Immunol 1999; 50: 427-32
9. Fishman D, Faulds G, Jeffery R et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102 (7): 1369-76
10. Jahromi M, Millward A, Demaine A. A CA repeat polymorphism of the IFN-gamma gene is associated with susceptibility to type 1 diabetes. J Interferon Cytokine Res 2000; 20 (2): 187-90
11. Obayashi H, Nakamura N, Fukui M et al. Influence of TNF microsatellite polymorphisms (TNFa) on age-at-onset of insulindependent diabetes mellitus. Hum Immunol 1999; 60 (10): 974-8
12. Stuber F, Petersen M, Bokelmann F, Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 1996; 24 (3): 381-4
13. Golovleva I, Saha N, Beckman L. Ethnic differences in interferonalpha allele frequencies. Hum Hered 1997; 47 (4): 185-8
14. Cox ED, Hoffmann SC, DiMercurio BS et al. Cytokine polymorphic analyses indicate ethnic differences in the allelic distribution of interleukin-2 and interleukin-6. Transplantation 2001; 72 (4): 720-6
15. Scarel-Caminaga RM, Trevilatto PC, Souza AP, Brito RB, Line SR. Frequencies of the -330 (T->G) IL-2 and -590 (T->C) IL-4 gene polymorphisms in a population from south-eastern Brazil. Eur J Immunogenet 2002; 29 (4): 293-6
16. Uboldi de Capei MU, Dametto E, Fasano ME, Rendine S, Curtoni ES. Genotyping for cytokine polymorphisms: allele frequencies in the Italian population. Eur J Immunogenet 2003; 30 (1): 5-10
17. Costeas PA, Koumas L, Koumouli A, Kyriakou-Giantsiou A, Papaloizou A. Cytokine polymorphism frequencies in the Greek Cypriot population. Eur J Immunogenet 2003; 30 (5): 341-3
18. Visentainer JE, Sell AM, da Silva GC et al. TNF, IFNG, IL6, IL10 and TGFB1 gene polymorphisms in South and Southeast Brazil. Int J Immunogenet 2008; 35 (4-5): 287-93
19. Meenagh A, Williams F, Ross OA et al. Frequency of cytokine polymorphisms in populations from western Europe, Africa, Asia, the Middle East and South America. Hum Immunol 2002; 63 (11): 1055-61
20. Hutchinson IV, Turner DM, Sankaran D, Awad MR, Sinnott PJ. Influence of cytokine genotypes on allograft rejection. Transplant Proc 1998; 30 (3): 862-3
21. Hutchinson IV, Turner D, Sankaran D, Awad M, Pravica V, Sinnott P. Cytokine genotypes in allograft rejection: guidelines for immunosuppression. Transplant Proc 1998; 30 (8): 3991-2
22. Hutchinson IV, Pravica V, Hajeer A, Sinnott PJ. Identification of high and low responders to allografts. Rev Immunogenet 1999; 1 (3): 323-33
23. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148 (2): 209-14
24. Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes 2005; 54 (Suppl 2): S114-24
25. Dubinski A, Zdrojewicz Z. The role of interleukin-6 in development and progression of atherosclerosis (in Polish). Pol Merkur Lekarski 2007; 22 (130): 291-4
26. Dowlati Y, Herrmann N, Swardfager W et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67 (5): 446-57
27. Swardfager W, Lanctot K, Rothenburg L, Wong A, Cappell J, Herrmann N. A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry 2010; 68 (10): 930-41
28. Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 2004; 13 (5): 339-43
29. Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 2001; 12 (1): 33-40
30. Nishimoto N. Interleukin-6 in rheumatoid arthritis. Curr Opin Rheumatol 2006; 18 (3): 277-81
31. Rauramaa R, Vaisanen SB, Luong LA et al. Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20 (12): 2657-62
32. Rundek T, Elkind MS, Pittman J et al. Carotid intima-media thickness is associated with allelic variants of stromelysin-1, interleukin-6, and hepatic lipase genes: the Northern Manhattan Prospective Cohort Study. Stroke 2002; 33 (5): 1420-3
33. Basso F, Lowe GD, Rumley A, McMahon AD, Humphries SE. Interleukin-6 -174G>C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS). Arterioscler Thromb Vasc Biol 2002; 22 (4): 599-604
34. Flex A, Gaetani E, Pola R et al. The -174 G/C polymorphism of the interleukin-6 gene promoter is associated with peripheral artery occlusive disease. Eur J Vasc Endovasc Surg 2002; 24 (3): 264-8
35. Pola R, Gaetani E, Flex A et al. -174 G/C interleukin-6 gene polymorphism and increased risk of multi-infarct dementia: a case-control study. Exp Gerontol 2002; 37 (7): 949-55
36. Burzotta F, Iacoviello L, Di Castelnuovo A et al. Relation of the -174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization. Am J Cardiol 2001; 88 (10): 1125-8
37. World Health Organization. Causes of death 2008: data sources and methods. Geneva, WHO, 2010
38. Groux H, Bigler M, de Vries JE, Roncarolo MG. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med 1996; 184 (1): 19-29
39. Groux H, Bigler M, de Vries JE, Roncarolo MG. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J Immunol 1998; 160 (7): 3188-93
40. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol 1993; 11: 165-90
41. Hajeer AH, Lazarus M, Turner D et al. IL-10 gene promoter polymorphisms in rheumatoid arthritis. Scand J Rheumatol 1998; 27 (2): 142-5
42. Mok CC, Lanchbury JS, Chan DW, Lau CS. Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum 1998; 41 (6): 1090-5
43. Lazarus M, Hajeer AH, Turner D et al. Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus. J Rheumatol 1997; 24 (12): 2314-7
44. Suarez A, Lopez P, Mozo L, Gutierrez C. Differential effect of IL10 and TNF(alpha) genotypes on determining susceptibility to discoid and systemic lupus erythematosus. Ann Rheum Dis 2005; 64 (11): 1605-10
45. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104 (4): 487-501
46. Lee YH, Harley JB, Nath SK. Meta-analysis of TNF-alpha promoter -308 A/G polymorphism and SLE susceptibility. Eur J Hum Genet 2006; 14 (3): 364-71
47. Brynskov J, Foegh P, Pedersen G et al. Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut 2002; 51 (1): 37-43
48. Lopez P, Gutierrez C, Suarez A. IL-10 and TNFalpha genotypes in SLE. J Biomed Biotechnol 2010; 2010: 838390
49. Al-Arfaj AS, Al-Balla SR, Al-Dalaan AN et al. Prevalence of systemic lupus erythematosus in central Saudi Arabia. Saudi Med J 2002; 23 (1): 87-9
50. Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003; 48 (7): 1849-52
51. Padyukov L, Lampa J, Heimburger M et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 2003; 62 (6): 526-9
52. Lopez P, Gomez J, Mozo L, Gutierrez C, Suarez A. Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs. Arthritis Res Ther 2006; 8 (2): R42
53. Belardelli F. Role of interferons and other cytokines in the regulation of the immune response. APMIS 1995; 103 (3): 161-79
54. Muller U, Steinhoff U, Reis LF et al. Functional role of type 1 and type 2 interferons in antiviral defense. Science 1994; 264 (5167): 1918-21